{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:45:22Z","timestamp":1648993522452},"reference-count":5,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.bulcan.2018.04.003","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T18:34:31Z","timestamp":1525286071000},"page":"545-546","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibiteurs de CDK4\/6\u00a0: biomarqueurs, m\u00e9canismes de r\u00e9sistance et \u00e9tude de l\u2019ADN tumoral circulant potentielle"],"prefix":"10.1016","volume":"105","author":[{"given":"Anthony","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.04.003_bib0030","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.04.003_bib0035","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.04.003_bib0040","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.04.003_bib0045","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O\u2019Leary","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.bulcan.2018.04.003_bib0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1093\/annonc\/mdx784","article-title":"Polyclonal RB1\u00a0mutations and acquired resistance to CDK 4\/6\u00a0inhibitors in patients with metastatic breast cancer","volume":"29","author":"Condorelli","year":"2018","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118301310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,16]],"date-time":"2018-06-16T06:21:02Z","timestamp":1529130062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118301310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":5,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0007455118301310"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.04.003","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiteurs de CDK4\/6\u00a0: biomarqueurs, m\u00e9canismes de r\u00e9sistance et \u00e9tude de l\u2019ADN tumoral circulant potentielle","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}